ReviewHistology and histopathology2026
Immunomodulation by collagen VI across fibrotic and tumor microenvironmental contexts.
Review in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The extracellular matrix (ECM) plays fundamental roles in modulating tissue structure and function under normal and pathological conditions. ECM composition is an essential consideration for studying cellular microenvironments, as varied composition leads to changes in cell behavior and delivery of therapeutics. Collagen VI is a non-fibrillar collagen that is found in both fibrotic and tumor microenvironments, where it promotes disease progression and suppresses the immune system. In this review, we summarize the contributions of collagen VI to fibrosis and tumor progression, followed by a focus on its ability to modulate the immune system in these contexts. Finally, we explore whether collagen VI could be a suitable therapeutic target for future study. While many studies have demonstrated the importance of collagen VI in disease progression, further studies of its immunomodulation abilities are needed to fully realize its potential as a therapeutic target in fibrosis and the tumor microenvironment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.